Articles from CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation

Company reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing, as it advances its pivot toward a diversified, high-value pipeline

By CNS Pharmaceuticals, Inc. · Via ACCESS Newswire · August 12, 2026